Who is sponsoring NCT00698893?

NCT00698893 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00698893?

Interventions in NCT00698893: Herpes simplex candidate (gD) vaccine GSK208141.

What condition does NCT00698893 study?

NCT00698893 studies Herpes Simplex.

Is NCT00698893 still recruiting?

NCT00698893 is currently completed. Last updated 2 June 2017.

Last reviewed 2017-06-02 · How we verify

NCT00698893

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults

Completed Phase 1 Last updated 2 June 2017

What this trial tests

Phase 1 trial testing Herpes simplex candidate (gD) vaccine GSK208141 in Herpes Simplex in 16 participants. Completed in 1 July 1992.

Timeline

1 May 1992

Primary endpoint
1 July 1992

1 July 1992

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	16
Start date	1 May 1992
Primary completion	1 July 1992
Estimated completion	1 July 1992

Drugs / interventions tested

Herpes simplex candidate (gD) vaccine GSK208141 — full drug profile →

Conditions studied

Herpes Simplex — all drugs for Herpes Simplex →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 40, any sex, with Herpes Simplex. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the safety and reactogenicity of candidate gD vaccine, with or without MPL, in HSV-seropositive subjects. The immune response elicited in these subjects will also be evaluated.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A review of HSV pathogenesis, vaccine development, and advanced applications.
Bai L, Xu J, Zeng L, Zhang L, et al · · 2024 · cited 30× · PMID 39207577 · DOI 10.1186/s43556-024-00199-7
The Current State of Vaccine Development for Ocular HSV-1 Infection.
Royer DJ, Cohen A, Carr D. · · 2015 · cited 21× · PMID 25983856 · DOI 10.1586/17469899.2015.1004315
Tackling cutaneous herpes simplex virus disease with topical immunomodulators-a call to action.
Duarte LF, Carbone-Schellman J, Bueno SM, Kalergis AM, et al · · 2025 · cited 4× · PMID 39982077 · DOI 10.1128/cmr.00147-24

Verify or expand the search:

Other recruiting trials for Herpes Simplex

Currently open trials in the same condition.

NCT04065971 — Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections. · Phase 4 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00698893 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 2 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00698893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing